Posts

Showing posts with the label Short Bowel Syndrome (SBS)

Short Bowel Syndrome (SBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Short bowel syndrome (SBS) is a condition marked by reduced digestive and absorptive capabilities, often stemming from surgical removal, congenital defects, or bowel diseases. This absorption deficiency leads to nutritional and electrolyte imbalances. In adults, SBS is typically defined as having less than 180 to 200 centimeters of remaining small bowel (in contrast to the normal range of 275 to 850 cm), necessitating nutritional and fluid supplementation. Patients exhibit malabsorption-related symptoms like weight loss, diarrhea, steatorrhea, dehydration, malnutrition, and electrolyte disturbances. SBS is an uncommon malabsorptive disorder primarily caused by extensive surgical small intestine resection, resulting in significant morbidity, mortality, and a reduced quality of life. Parenteral nutrition is generally unnecessary for those with over 180 cm of small bowel. Those with over 90 cm may require it for less than a year, while those with less than 60 cm will likely need life...

Short Bowel Syndrome (SBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Short bowel syndrome (SBS) is characterized by reduced digestion and absorption ability due to surgical resection, a congenital defect, or bowel disease. This absorption failure results in nutritional and electrolyte imbalances. Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm), leading to the need for nutritional and fluid supplements. Patients present with signs and symptoms of malabsorption such as weight loss, diarrhea, steatorrhea, dehydration, malnutrition, and electrolyte imbalance. SBS is an uncommon malabsorptive condition most frequently caused by massive surgical resection of the small intestine associated with significant morbidity and mortality and reduced quality of life. ·        According to Thelansis disease modeling data and literature reviews, the estimated prevalence ranges between 22.5 to 33 cases per million population in the USA. · ...